For over a year now, it’s been clear that a bubble was building in artificial intelligence. But the bubble has not only gotten bigger; the market didn’t think the music would stop. Over the past month, the music simply stopped playing, and everything changed. We never know what the catalyst of a bubble bursting is going to be, but in the case of AI it was Jensen Huang’s transgressions and eventual resignation from $NVIDIA(NVDA)$ ( ▼ 4.12% ). There were signs of distress, like rising bond rates for data center companies, but it was Huang who caused the hype train to stop. As much as I think the AI bubble bursting will be healthy and provide long-term opportunities, I’m also fully aware there will be collateral damage. The blast radius of a bubble d
Shares of $Hims & Hers Health Inc.(HIMS)$ ( ▲ 8.78% ) have fallen nearly 30% over the past week, which isn’t the performance I’m looking for from what was the biggest holding in the Asymmetric Portfolio. There were some positives in the company’s third-quarter 2026 results, but under the headline growth rate, there was a lot to be desired on several fronts, so the market’s reaction was understandable. The question for investors now isn’t whether Q3 was good or if Q4 will be better (it probably won’t be). Attention now turns to 2027. Management explicitly stated that it’s saving dry powder for a big push in 2027. If that works, this could be a leader in the booming peptide market and get lifelong customers who come in through labs, peptides, GL
$HIMS Revenue Grows 49% as Subscriber Mix Shifts Upmarket
📊 $Hims & Hers Health Inc.(HIMS)$ : Subscriber Decline Doesn't Tell the Whole Story A decline in subscribers isn't ideal, but it's happening alongside a much higher price point. My read is that $HIMS is shifting toward higher-value, higher-revenue subscribers in areas like weight loss, while allowing lower-value customers in ED and hair loss to churn. That could be a worthwhile trade-off, but it also makes the headline subscriber numbers harder to interpret without more detail on customer mix and revenue per subscriber. The earnings "miss" also needs to be viewed in the context of management's comments: "Revenue grew 49% year-over-year, our second consecutive quarter of acceleration, with domestic revenue up 21% year-over-year and internationa
It’s been a wild week for the stock market. The AI trade seems to be taking a breather, if not worse. Investors are starting to worry about growth, margins, and valuations for some of the most talked-about stocks on the market. Even the biggest companies in the world saw their stocks fall 10% earlier this week. Longtime readers know I’ve been somewhat cautious about the market for most of the past year. I’ve sold part of my position in Robinhood and Alphabet on valuation concerns. But that caution has also led to the Asymmetric Portfolio underperforming the market over the past year. The reason was simple. I didn’t get in on the AI trade. I didn’t buy Neoclouds because I don’t think they have a sustainable business model. I’m not buying semiconductors or memory stocks that I think are appr
What I’m Buying in November 2026: 4 Stocks Added, 1 Sold
I'm selling 1 stock and adding 4 new positions to my portfolio this month. The goal remains the same: build a concentrated portfolio of companies with the potential to deliver 10x returns over the next decade. 💰 The Asymmetric Portfolio Strategy Each month, I'll invest $500 in new capital, selecting from my Asymmetric Universe of 25 companies. The allocation rules are straightforward: Monthly investment: $500. If the $S&P 500(.SPX)$ or $NASDAQ(.IXIC)$ falls 20% below its all-time high, monthly investment increases to $1,000. If either index falls 30%, monthly investment increases to $1,500, with further increases as the market declines. Any stock in the Asymmetric Universe can be selected. Stocks can
Hims & Hers: Testosterone, Peptides, and a Podcast
$Hims & Hers Health Inc.(HIMS)$ ( ▼ 8.82% ) may be the most controversial stock in the Asymmetric Portfolio. Some investors think it’s a disruptive company with 10x+ potential. Others think it’s a parasite on society. Hims & Hers’ Catalysts There’s a story in any stock. A rise. A fall. And with Hims & Hers, the story is ongoing and volatile. I’ll be back with more on the story after earnings early next week, but I thought we should cover some of the latest with the company. The Value I’m going to start with the value, or what we pay as investors. Hims & Hers is in its high growth phase, so we shouldn’t be valuing the company based on earnings or free cash flow. The price-to-sales multiple is the most appropriate, and shares trade n
$Alphabet(GOOG)$ fell 12.3% last week and are down 26.8% over the past six months. Yes, I sold about a third of my Alphabet shares in July based on valuation concerns and the company entering a phase of negative free cash flow. But I didn’t see this reaction coming. I’ve been critical of a lot of the AI stocks out there because I think businesses like neoclouds are unsustainable and commodity suppliers like Micron will… commoditize. But Alphabet is king of the tech mountain and should be fine long-term. Still, the market punished shares because there are signs of disruption. Search isn’t growing the way it was expected to, and that puts the cash flow to fund AI into question. Here are my thoughts on the nuance and realities (both good and bad) at
$GOOG Delivers $125B in Revenue, Grows 25% — So Why the Selloff?
The market may be nitpicking a few numbers, but zoom out for a second: $Alphabet(GOOG)$ generated $125 billion in quarterly revenue, grew 25% year over year, and expanded margins. That’s an incredible business. 🎯 So why the disappointment? One factor being discussed is the mark-to-market impact tied to $SpaceX(SPCX)$ , which may have affected the reported results. After listening to the entire earnings call, I came away impressed. The underlying business still looks strong, and the growth story remains compelling. 💡 If the market wants to offer a discount on a business like this, I’m paying attention. Sometimes the opportunity comes when investors focus on the noise instead of the fundamentals. Markets ar
Anthropic’s S-1: $500B in Obligations, 45% Quarterly Growth
$Anthropic(ANT)$ ’s S-1 Is Here! It’s all hands on deck. I had something else prepared for this morning, but when the biggest IPO filing we’ve ever seen hit, it’s time to call an audible. We got official numbers from Anthropic, the fastest-growing company at scale that I’ve ever seen, and a potential $2 trillion IPO within the next month. It’s impressive. It’s scary. And it’s holding up the market. I’ll get to the Anthropic S-1 and what I took from it in a moment. Anthropic’s S-1 If you’ve never seen an S-1, the financial filing a company makes before going public, this is an interesting one. Find the S-1 here. Anthropic is not only a well-known company, but it’s also arguably the most important in the AI buildout. The company has ~$500 billion in
$ANT S-1: 45% Quarterly Growth, $390B in Commitments
$Anthropic(ANT)$ ’s S-1 appears to confirm roughly 45% Q/Q revenue growth in Q3. The filing also says that from Sep. 2025 to Sep. 2026, TTM revenue grew ~1,200%, while headcount rose ~170%. Revenue per employee jumped from $1.4M to over $6.6M. But the bigger concern may be the obligations section. $ANT has at least $390B in non-cancellable spending commitments over the next decade tied to $MSFT, $GOOG, and $AMZN. The $SPCX deal is also massive, though it reportedly includes exit options. That puts enormous pressure on revenue to keep scaling rapidly. Growth is impressive, but the commitments make execution critical. The market will be watching whether $ANT can grow into those obligations. $Microsoft(MSFT)$